Core Insights - The Shenzhen-Hong Kong Stock Connect Medical Index (983036) closed at 4391.58 points, up 0.14%, with a trading volume of HKD 8.259 billion and a turnover rate of 0.75% [1] - Among the index constituents, 32 stocks rose while 24 fell, with Mai Rui Medical leading the gainers at 3.65% and Jian Kang Zhi Lu leading the decliners at 3.41% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Stock Connect Medical Index are as follows: - Mai Rui Medical (sz300760) holds a weight of 14.56%, latest price at HKD 196.30, with a market cap of HKD 238 billion and a gain of 1.50% [1] - Yan Er Eye Hospital (sz300015) has a weight of 11.62%, latest price at HKD 11.40, with a market cap of HKD 106.31 billion and a decline of 0.26% [1] - Le Jin Medical (sz300003) has a weight of 4.85%, latest price at HKD 15.87, with a market cap of HKD 2.93 billion and a slight gain of 0.13% [1] - Ai Mei Ke (sz300896) has a weight of 4.80%, latest price at HKD 146.26, with a market cap of HKD 44.26 billion and a gain of 0.83% [1] - Yu Yue Medical (sz002223) has a weight of 4.66%, latest price at HKD 35.70, with a market cap of HKD 35.79 billion and a decline of 0.67% [1] - Ying Ke Medical (sz300677) has a weight of 3.64%, latest price at HKD 41.53, with a market cap of HKD 27.21 billion and a gain of 1.94% [1] - Fu Rui Co., Ltd. (sz300049) has a weight of 3.59%, latest price at HKD 67.08, with a market cap of HKD 17.78 billion and a gain of 1.36% [1] - Mei Nian Health (sz002044) has a weight of 3.58%, latest price at HKD 5.28, with a market cap of HKD 20.67 billion and a decline of 1.68% [1] - China National Pharmaceutical (hk01099) has a weight of 3.35%, latest price at HKD 18.42, with a market cap of HKD 57.48 billion and a decline of 0.69% [1] - Ping An Good Doctor (hk01833) has a weight of 2.63%, latest price at HKD 13.66, with a market cap of HKD 29.52 billion and a decline of 1.83% [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled HKD 58.83 million, while retail investors saw a net inflow of HKD 78.07 million [1] - The detailed capital flow for the top stocks shows: - Ai Mei Ke (300896) had a main fund net inflow of HKD 46.99 million but a retail net outflow of HKD 30.07 million [2] - Mai Rui Medical (300760) experienced a main fund net inflow of HKD 33.08 million with retail outflows [2] - Other stocks like Fu Rui Co., Ltd. (300049) and Li Bang Instruments (300206) also showed mixed capital flows with net inflows from main funds but outflows from retail investors [2] Recent Adjustments - In the past 10 days, there has been an adjustment in the Shenzhen-Hong Kong Stock Connect Medical Index, with one new stock added [2]

Core Points - The Biotech Index (970038) closed at 2134.66 points, down 0.06%, with a trading volume of 13.045 billion yuan and a turnover rate of 0.95% [1] - Among the index constituents, 22 stocks rose while 27 fell, with Hualan Vaccine leading the gainers at 2.57% and Jingxin Pharmaceutical leading the decliners at 5.97% [1] Index Constituents Summary - The top ten constituents of the Biotech Index include: - Mindray Medical (12.58% weight, latest price 196.30 yuan, market cap 238 billion yuan) [1] - Changchun High-tech (4.87% weight, latest price 99.66 yuan, market cap 40.655 billion yuan) [1] - Shimi Aoshi (4.74% weight, latest price 6.60 yuan, market cap 4.3811 billion yuan) [1] - Kanglong Chemical (4.55% weight, latest price 28.87 yuan, market cap 51.337 billion yuan) [1] - Tigermed (4.54% weight, latest price 51.20 yuan, market cap 44.085 billion yuan) [1] - Deep Technology (4.16% weight, latest price 23.42 yuan, market cap 36.809 billion yuan) [1] - Muyuan Food (3.62% weight, latest price 49.90 yuan, market cap 272.592 billion yuan) [1] - Lepu Medical (3.19% weight, latest price 15.87 yuan, market cap 29.255 billion yuan) [1] - Aimeike (3.16% weight, latest price 146.26 yuan, market cap 44.257 billion yuan) [1] - Seeyou Medical (3.07% weight, latest price 35.70 yuan, market cap 35.788 billion yuan) [1] Capital Flow Analysis - The Biotech Index constituents experienced a net outflow of 84.2481 million yuan from institutional investors, while retail investors saw a net inflow of 67.1618 million yuan [1] - Notable capital flows include: - Muyuan Food: 104 million yuan net inflow from institutional investors, but net outflows from retail and speculative investors [2] - Aimeike: 46.9918 million yuan net inflow from institutional investors, with outflows from retail and speculative investors [2] - Mindray Medical: 33.0761 million yuan net inflow from institutional investors, with outflows from retail and speculative investors [2]

Core Insights - The ChiNext Medical Index (970082) closed at 3661.9 points on November 27, with a slight increase of 0.18% and a trading volume of 8.516 billion yuan, reflecting a turnover rate of 1.15% [1] - Among the index constituents, 27 stocks rose while 22 fell, with Lexin Medical leading the gainers at 2.04% and Dean Diagnostics leading the decliners at 2.96% [1] Index Constituents Summary - The top ten constituents of the ChiNext Medical Index include: - Yuaner Eye Hospital (sz300015) with a weight of 8.87% and a latest price of 11.40, down by 0.26% [1] - Mindray Medical (sz300760) with a weight of 8.02% and a latest price of 196.30, up by 1.50% [1] - Kanglong Chemical (sz300759) with a weight of 7.41% and a latest price of 28.87, down by 0.07% [1] - Tigermed (sz300347) with a weight of 7.40% and a latest price of 51.20, up by 0.23% [1] - Lepu Medical (sz300003) with a weight of 5.65% and a latest price of 15.87, up by 0.13% [1] - New Industry (sz300832) with a weight of 5.17% and a latest price of 58.28, down by 0.99% [1] - Aimeike (sz300896) with a weight of 5.15% and a latest price of 146.26, up by 0.83% [1] - Yingke Medical (sz300677) with a weight of 4.24% and a latest price of 41.53, up by 1.94% [1] - Furuijia (sz300049) with a weight of 4.18% and a latest price of 67.08, up by 1.36% [1] - BGI Genomics (sz300676) with a weight of 3.07% and a latest price of 46.37, down by 0.39% [1] Capital Flow Analysis - On the same day, the ChiNext Medical Index constituents experienced a net outflow of 114 million yuan from institutional investors and 105 million yuan from retail investors, while retail investors saw a net inflow of 220 million yuan [1] - Detailed capital flow for selected stocks includes: - Aimeike (sz300896) with a net inflow of 46.9918 million yuan from institutional investors [2] - Lexin Medical (sz300562) with a net inflow of 41.5425 million yuan from institutional investors [2] - Mindray Medical (sz300760) with a net inflow of 33.0761 million yuan from institutional investors [2] - Furuijia (sz300049) with a net inflow of 13.6788 million yuan from institutional investors [2]

迈瑞医疗（300760）(300760.SZ)公告，公司实际控制人之一、董事长李西廷先生拟以集中竞价交易方 式增持公司股份，本次拟增持金额约2亿元(含交易费用);实施期限自2025年11月27日起6个月内。 于2025年11月27日，李西廷先生已通过集中竞价交易方式增持公司股份共计15.23万股，增持均价为 196.862元/股，合计增持金额2998.99万元。 ...

智通财经APP讯，迈瑞医疗(300760.SZ)公告，公司实际控制人之一、董事长李西廷先生拟以集中竞价交 易方式增持公司股份，本次拟增持金额约2亿元(含交易费用);实施期限自2025年11月27日起6个月内。 于2025年11月27日，李西廷先生已通过集中竞价交易方式增持公司股份共计15.23万股，增持均价为 196.862元/股，合计增持金额2998.99万元。 ...

人民财讯11月27日电，迈瑞医疗（300760）11月27日公告，公司实控人之一、董事长李西廷拟通过深圳 证券交易所以集中竞价交易方式增持公司股份，本次拟增持金额为2亿元(含交易费用)，实施期限为自 2025年11月27日起6个月内。 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Insights - The pharmaceutical sector has underperformed the overall market, with a significant decline in various sub-sectors, including a 6.88% drop in the biotechnology sector [1][32] - Hidradenitis Suppurativa (HS) is identified as a chronic, recurrent inflammatory skin disease with a low prevalence in China and the U.S., highlighting the potential market for treatment options [2][10] - The report emphasizes the increasing market share of new biologics targeting IL-17A and IL-17A/F, which are expected to outperform traditional therapies like Adalimumab [17][18][22] Summary by Sections Market Performance - The overall A-share market declined by 4.32%, with the biotechnology sector falling by 6.88%, indicating a weaker performance compared to the broader market [1][32] - Specific declines were noted in chemical pharmaceuticals (7.02%), biological products (7.46%), and medical services (6.90%) [1][32] Hidradenitis Suppurativa (HS) Overview - HS affects approximately 0.03% of the population in China, with around 400,000 cases, and has been included in the rare disease directory [2][10] - The disease's complex pathogenesis involves multiple immune pathways, making it a target for various therapeutic approaches [11][27] Investment Strategy - The report suggests focusing on undervalued stocks in the medical device and pharmacy sectors, which have already priced in risks from policy changes [42][43] - It highlights the potential for growth in the CXO sector, particularly in CDMO and clinical CRO segments, as they continue to show strong performance despite market challenges [42][43] Recommended Stocks - The report lists several companies with strong growth potential, including Mindray Medical, WuXi AppTec, and Aier Eye Hospital, all rated as "Outperform" [4][44] - Mindray Medical is noted for its robust R&D and international expansion, while WuXi AppTec is recognized for its comprehensive drug development services [44]

Overall Viewpoint - The core viewpoint of the report emphasizes that demand is the source of strength and innovation is the light that breaks the deadlock in the pharmaceutical industry. The continuous demand for pharmaceuticals and the increasing unmet needs drive pharmaceutical companies to invest in research and development, leading to explosive revenue and stock price growth [5][7][13]. Innovation Drugs - China has become a significant participant in global innovative drug research and development, with a high-quality growth rate of therapies in development far exceeding the global average. The domestic innovative drug sector is entering a revenue era driven by innovation, creating a positive dynamic between traditional pharmaceutical companies and emerging players [5][7][27]. - The number of domestic new drug overseas authorizations has surpassed $10 billion since 2021, indicating a sustained increase in overseas authorization activity, which continues to propel China's innovative drugs into the global market [5][7][27]. Pharmaceutical Industry - The report indicates that the innovative layout in the pharmaceutical industry is beginning to yield results, with performance expected to accelerate. Many companies are transitioning to a growth phase driven by innovation, suggesting that the current period is just the beginning of a more significant performance acceleration [5][7][27]. CXO Sector - Starting in the second half of 2024, global pharmaceutical research and development demand is expected to gradually recover, with strong demand for new molecular types such as peptides and ADCs driving growth in the CDMO segment. The value of leading CRO companies is anticipated to further highlight as the difficulty and barriers in drug development increase [5][7][27]. API Sector - The core business of API companies is primarily focused on non-U.S. exports (to Europe and India), with current demand remaining strong. Leading companies are achieving positive results in expanding into CDMO businesses, and many have integrated local market formulation businesses, which are expected to benefit from the easing of centralized procurement policies [5][7][27]. Medical Devices - The high-value consumables sector is experiencing a reduction in procurement pressure, with performance expected to return to a high growth trajectory. The report highlights that the bidding for medical devices is recovering, indicating an upcoming turning point for the sector, with optimism for domestic equipment technology upgrades and international expansion [5][7][27]. Traditional Chinese Medicine - The report expresses optimism for the recovery of the traditional Chinese medicine sector in 2026, with upward factors outweighing downward ones. The expected recovery sequence for sub-sectors includes hospital-based traditional Chinese medicine, four categories of drugs, OTC common drugs, and high-value consumer traditional Chinese medicine [5][7][27]. Medical Services - The report anticipates that with the introduction of several positive macro policies, consumer expectations are likely to recover. If favorable local fiscal policies are implemented, the bad debts and payment cycles for private hospitals will also see substantial relief, alleviating market concerns [5][7][27]. Pharmaceutical Retail - The pharmaceutical retail sector has faced continuous pressure since Q3 2024, primarily due to declining demand for four categories of drugs, consumption downgrading, intensified competition, and fluctuations in medical insurance policies. However, as high baselines are gradually digested, the revenue growth of leading chains is expected to stabilize and improve [5][7][27]. Blood Products - Despite short-term performance pressures, the essential nature of blood products indicates that supply and demand are expected to rebalance. The diversity of products among companies is rapidly increasing, with high-value new products like immunoglobulin expected to drive industry growth [5][7][27]. Life Sciences Services - The life sciences services sector is experiencing a demand recovery, coupled with deepening domestic substitution and ongoing overseas expansion, leading to a positive quarterly revenue growth starting from Q4 2024. The net profit margin of the sector has been gradually improving, indicating sustained profitability [5][7][27].

Industry Overview - The year 2025 is regarded as the "year of brain-computer interfaces" in China, with significant policy support and investment activity in the sector [1][2] - The "14th Five-Year Plan" has identified brain-computer interfaces as one of the six key future industries for strategic development [4] Policy Support - In July, multiple government departments released implementation opinions to promote innovation and development in the brain-computer interface industry, setting clear development timelines [3] - By 2027, breakthroughs in key technologies are expected, with the establishment of advanced technical, industrial, and standard systems [3] - By 2030, the industry aims to enhance innovation capabilities and cultivate globally influential leading enterprises [3] Investment Landscape - As of November, the brain-computer interface sector in China has completed 28 financing rounds, totaling over 5 billion yuan [1] - The brain-computer interface concept index (8841700.WI) has seen a 50.74% increase over the past year, outperforming the Shanghai and Shenzhen 300 index, which rose by 17.64% [1] Company Developments - A total of 24 companies in the A-share market are involved in the brain-computer interface sector, with average revenues of 3.428 billion yuan and average net profits of 431 million yuan in the first three quarters [8] - However, there is significant variance in performance, with 8 companies reporting losses and 11 companies with net profits below 100 million yuan [10] - Companies like Mindray Medical and 37 Interactive Entertainment reported net profits exceeding 1 billion yuan [10] Clinical Advancements - In June, China became the second country globally to conduct invasive clinical trials for brain-computer interfaces, marking a significant milestone in the field [6] - The "North Brain No. 1" GCP multi-center clinical trial was launched in October, representing the first high-throughput, wireless, fully implanted semi-invasive brain-computer system [7] Market Potential - The brain-computer interface industry is expected to grow rapidly, with companies like Lepu Medical and Meihua Medical actively pursuing commercialization of their products [10][11] - Lepu Medical is working on deep brain stimulation devices, while Meihua Medical collaborates with global cochlear implant leaders to develop invasive brain-computer interface products [10][11] - Aipeng Medical has received approval for its EEG collection products and is focusing on ADHD treatment solutions, with new pricing policies being introduced for brain-computer interface services [11]

Summary of Key Points from the Conference Call Industry Overview - The focus is on the **China A-shares market**, specifically the **CSI300 index** and its outlook for 2026. Core Insights and Arguments 1. **CSI300 Target Projections**: - The base-case target for the CSI300 by the end of 2026 is set at **5,200**, based on a **15.9x** P/E ratio and an estimated EPS of **Rmb328**, reflecting a **15% year-on-year growth** [1][4][5]. - Bear-case and bull-case targets are **4,000** and **6,000**, respectively [1][5]. 2. **Investment Themes for 2026**: - **Pro-equity "anti-involution" policies** are expected to enhance structural upside in net profit margin (NPM) and return on equity (ROE) for the CSI300, with consensus estimates of **12% NPM** and **11% ROE** [4]. - **AI Infrastructure Growth**: Anticipated capital expenditure growth in AI infrastructure globally will benefit Chinese suppliers, particularly those focused on localization and AI monetization [4]. - **Global Macro Support**: Easing fiscal and monetary policies globally will support offshore sales for listed companies [4]. - **K-shaped Recovery in Consumption**: This recovery is expected to benefit both low-end and luxury consumption sectors [4]. 3. **Downside Risks**: - Potential cuts to consensus EPS estimates for Q4 2025, especially in the **IT** and **Healthcare** sectors [4]. - The continuation of a "high-quality development" approach may dampen mid-range aspirational consumption [4]. - Geopolitical tensions, particularly between the US and China, could pose risks, especially with upcoming elections [4]. 4. **Potential Policy Changes**: - The onset of a non-performing loan (NPL) cycle may lead to new policies aimed at supporting physical properties [4]. - Increased efficiency from AI and digitalization may necessitate enhanced social security coverage due to job dislocations [4]. 5. **Thematic Stock Screens**: - Focus on **IT and Healthcare A-shares** that demonstrate innovation potential, with metrics such as market capitalization and overseas revenue [4]. - Screening for top A-share listings across various sectors including **autos, battery materials, lithium, solar, cement, chemicals, coal, steel, dairy, hogs, liquor, and logistics** [4][10]. Additional Important Insights - The **CSI300 index** is projected to have an implied upside of **17%** from the current level to the base-case target, while the bear-case scenario indicates a **10% downside** [5]. - The report highlights a shift from value to growth stocks expected by early 2026, particularly in the context of the **IT** and **Healthcare** sectors [4]. - The **A-share market** has shown robust margin financing, indicating strong investor confidence [14]. This summary encapsulates the key points discussed in the conference call, providing a comprehensive overview of the outlook for the China A-shares market and the CSI300 index for 2026.